Tirzepatide Reference Overview

Compound Reference Overview

Field Value
Name Tirzepatide
Reference Code GLP-1TZ
Category Dual GIP / GLP-1 Receptor Agonist
Example Strengths 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (FDA-approved pen strengths); compounded formulations vary
Reference Range 2.5 mg – 15 mg once weekly (evaluated in SURPASS and SURMOUNT clinical trials)
Frequency Once weekly (clinical reference)
Key Safety Warning Boxed Warning: Risk of thyroid C-cell tumors observed in rodent studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Mechanism of Action (Educational)

Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Simultaneous activation of both incretin pathways enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite through central hypothalamic signaling.

The addition of GIP receptor agonism differentiates tirzepatide from GLP-1–only agents, potentially contributing to amplified effects on glycemic control and body weight reduction observed in clinical trials.

Indications (Literature)

  • Type 2 diabetes mellitus (SURPASS clinical trial program)
  • Chronic weight management in adults with obesity or overweight (SURMOUNT clinical trial program)
  • Obstructive sleep apnea in patients with obesity (recent clinical trial data)
  • Investigational use in cardiometabolic and heart failure populations

Administration (Clinical)

Parameter Details
Route Subcutaneous
Frequency Once weekly
Injection Sites Abdomen, thigh, or upper arm (rotate sites)
Timing Administered on the same day each week, with or without food

Pharmacokinetics (Clinical)

Published pharmacokinetic studies report an approximate half-life of ~5 days, supporting once-weekly administration. Peak plasma concentrations are typically achieved within 24–48 hours after injection.

Steady-state levels are generally reached after approximately 4 weeks of weekly dosing. Metabolism occurs through proteolytic degradation into inactive fragments, which are subsequently eliminated via renal and fecal pathways.

Titration Schedule (Clinical)

The following dose-escalation sequence reflects regimens evaluated in major clinical trials and is provided for literature reference only.

  • Weeks 1–4: 2.5 mg once weekly (initiation dose)
  • Weeks 5–8: 5 mg once weekly
  • Weeks 9–12: 7.5 mg once weekly
  • Weeks 13–16: 10 mg once weekly
  • Weeks 17–20: 12.5 mg once weekly
  • Week 21+: 15 mg once weekly (maximum evaluated dose)

Gradual escalation has been associated with improved gastrointestinal tolerability and reduced early discontinuation.

Reconstitution & Concentration
(Mathematical Standardization Model)

For educational standardization purposes, concentration may be normalized so that 0.10 mL (10 insulin units) = 2.5 mg. This supports clean unit-to-milligram conversion across investigational escalation stages.

Parameter Value
Target Concentration 25 mg/mL
Unit Conversion 0.10 mL (10 units) = 2.5 mg
Example (15 mg vial) Reconstitute with 0.6 mL bacteriostatic water → 25 mg/mL
Stability Up to 28 days refrigerated (varies by compounding standards and formulation)

Conversion Reference

  • 10 units = 2.5 mg
  • 20 units = 5 mg
  • 30 units = 7.5 mg
  • 40 units = 10 mg
  • 50 units = 12.5 mg
  • 60 units = 15 mg

This section is provided strictly for arithmetic illustration and does not constitute dosing guidance. FDA-approved tirzepatide products are supplied as prefilled pen devices and are not reconstituted in this manner.

Safety & Contraindications (Summary)

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • Known hypersensitivity to tirzepatide or formulation components
  • Pregnancy or breastfeeding

Relative Cautions

  • History of pancreatitis
  • Severe gastrointestinal disease (e.g., gastroparesis)
  • Concomitant insulin or sulfonylurea therapy

Adverse Events

  • Nausea
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Constipation
  • Alopecia (reported in weight-management trials)

Serious Adverse Events

  • Pancreatitis
  • Gallbladder disease
  • Hypoglycemia (primarily when combined with insulin or sulfonylureas)
  • Acute kidney injury (typically secondary to dehydration)

Drug Interactions

  • Insulin or sulfonylureas may increase risk of hypoglycemia
  • Delayed gastric emptying may alter absorption of certain oral medications

Monitoring (Clinical)

  • HbA1c (every 3 months in diabetes management)
  • Fasting glucose levels
  • Body weight and BMI
  • Renal function (if significant gastrointestinal symptoms occur)
  • Symptoms suggestive of pancreatitis or gallbladder disease
  • Heart rate (mild increases observed in some patients)

Mathematical Calculation Tool

The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes.
This tool is provided strictly for arithmetic reference.

Peptide Reconstitution Calculator

For Educational & Professional Reference Only

⚠️ This is a mathematical reference tool only. No medical or dosing advice is provided.

Disclaimer

This content is provided strictly as a pharmacologic and mathematical reference for educational and professional purposes. It does not constitute medical advice, prescribing guidance, diagnosis, or treatment recommendations. All clinical decisions must be made by a licensed healthcare professional in accordance with applicable regulations.

Reference Sources